LQZ-7F
LQZ-7F, a survivin dimerization inhibitor, induces spontaneous apoptosis and synergizes with Docetaxel in prostate cancer cells. LQZ-7F dose-dependently inhibits survival of both PC-3 and C4-2 cells with IC50s of 2.99 and 2.47 μM, respectively[1].
Product Specifications
CAS Number
354543-09-2
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
Apoptosis; Survivin
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lqz-7f.html
Purity
97.44
Solubility
DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=NON=C1N)N/N=C2C3=C(C4=NC5=NON=C5N=C4\2)C=CC=C3
Molecular Formula
C14H7N9O3
Molecular Weight
349.26
Precautions
H315, H319, H320
References & Citations
[1]Robert Peery, et al. A novel survivin dimerization inhibitor without a labile hydrazone linker induces spontaneous apoptosis and synergizes with docetaxel in prostate cancer cells. Bioorg Med Chem. 2022 Jul 1;65:116761.|[2]Qi Jing, et al. Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors. Cancer Research. 2016 Jan. 76 (2) :453-462.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
